Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuichi Yoshida

Showing results (281-290 of 316) with videos related to

Pageof 32
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 4, 2023
Accuracy of the Enhanced Liver Fibrosis Test in Patients With Type 2 Diabetes Mellitus and Its Clinical ImplicationsTaeang Arai, Hirokazu Takahashi, Yuya Seko, et al.
Plos One|February 7, 2023
Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinomaKazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 11, 2013
Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapyTsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, et al.
Hepatology Communications|December 13, 2024
Accuracy of type IV collagen 7S versus Enhanced Liver Fibrosis score for diagnosing fibrosis in patients with metabolic dysfunction-associated steatotic liver diseaseHiroshi Ishiba, Hideki Fujii, Yoshihiro Kamada, et al.
Journal of Gastroenterology|November 24, 2011
Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirinTsugiko Oze, Naoki Hiramatsu, Changho Song, et al.
Gastro Hep Advances|April 20, 2026
Sequential Fibrosis-4 Index and Mac-2 Binding Protein Glycosylation Isomer Combination Improve Detection of Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Multicenter StudyAsahiro Morishita, Yoshihiro Kamada, Yoshio Sumida, et al.
Journal of Gastroenterology|January 11, 2012
Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infectionMika Kurokawa, Naoki Hiramatsu, Tsugiko Oze, et al.
Plos One|January 2, 2024
Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational studyMachiko Kai, Hayato Hikita, Maesaka Kazuki, et al.
Hepatology (Baltimore, Md.)|December 2, 2021
Sphingosine-1-phosphate promotes tumor development and liver fibrosis in mouse model of congestive hepatopathyHironari Kawai, Yosuke Osawa, Michitaka Matsuda, et al.
Journal of Gastroenterology|May 10, 2011
The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in JapanTsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, et al.
Pageof 32

Showing results (281-290 of 316) with videos related to

Sort By:
Pageof 32
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 4, 2023
Accuracy of the Enhanced Liver Fibrosis Test in Patients With Type 2 Diabetes Mellitus and Its Clinical ImplicationsTaeang Arai, Hirokazu Takahashi, Yuya Seko, et al.
Plos One|February 7, 2023
Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinomaKazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 11, 2013
Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapyTsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, et al.
Hepatology Communications|December 13, 2024
Accuracy of type IV collagen 7S versus Enhanced Liver Fibrosis score for diagnosing fibrosis in patients with metabolic dysfunction-associated steatotic liver diseaseHiroshi Ishiba, Hideki Fujii, Yoshihiro Kamada, et al.
Journal of Gastroenterology|November 24, 2011
Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirinTsugiko Oze, Naoki Hiramatsu, Changho Song, et al.
Gastro Hep Advances|April 20, 2026
Sequential Fibrosis-4 Index and Mac-2 Binding Protein Glycosylation Isomer Combination Improve Detection of Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Multicenter StudyAsahiro Morishita, Yoshihiro Kamada, Yoshio Sumida, et al.
Journal of Gastroenterology|January 11, 2012
Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infectionMika Kurokawa, Naoki Hiramatsu, Tsugiko Oze, et al.
Plos One|January 2, 2024
Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational studyMachiko Kai, Hayato Hikita, Maesaka Kazuki, et al.
Hepatology (Baltimore, Md.)|December 2, 2021
Sphingosine-1-phosphate promotes tumor development and liver fibrosis in mouse model of congestive hepatopathyHironari Kawai, Yosuke Osawa, Michitaka Matsuda, et al.
Journal of Gastroenterology|May 10, 2011
The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in JapanTsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, et al.
Pageof 32